Journal article

How do tumor cells respond to HDAC inhibition?

Andrea Newbold, Katrina J Falkenberg, H Miles Prince, Ricky W Johnstone

The FEBS Journal | WILEY | Published : 2016


It is now well recognized that mutations, deregulated expression, and aberrant recruitment of epigenetic readers, writers, and erasers are fundamentally important processes in the onset and maintenance of many human tumors. The molecular, biological, and biochemical characteristics of a particular class of epigenetic erasers, the histone deacetylases (HDACs), have been extensively studied and small-molecule HDAC inhibitors (HDACis) have now been clinically approved for the treatment of human hemopoietic malignancies. This review explores our current understanding of the biological and molecular effects on tumor cells following HDACi treatment. The predominant responses include induction of t..

View full abstract


Funding Acknowledgements

RWJ is funded by project and program grants from the National Health and Medical Research Council of Australia (NHMRC), an NHMRC Senior Principal Research Fellowship, and grants from the Cancer Council Victoria and the Victorian Cancer Agency (VCA). AN is funded by a postdoctoral fellowship provided by the Leukaemia Foundation of Australia. HMP is funded by the NHMRC, VCA, and the Snowdome Foundation.